Ligand Pharmaceuticals LGND Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $51.72M+14.1% | $59.67M+39.4% | $115.46M+123% | $47.63M+14.7% | $45.33M+46.3% | ||
| $2.15M-95.7% | $3.51M-20.7% | $21.02M+270% | $6.57M+22.7% | $50.09M+739% | ||
| $20.84M+10.8% | $25.03M-2.3% | $28.45M+16.2% | $20.18M+14.5% | $18.8M+71.7% | ||
| $34.35M-57.9% | $45.82M-12.6% | $60.53M+24.4% | $39.18M-35.4% | $81.55M+191% | ||
| $17.37M+148% | $13.84M+244% | $54.93M+1,648% | $8.44M+144% | -$36.22M-1,312% | ||
| 33.6%+113pp | 23.2%+45.7pp | 47.6%+41.5pp | 17.7%+63.7pp | -79.9%-89.5pp | ||
| $1.75M+101% | $1.79M+102% | $910K+22.8% | $1.15M-9.1% | $867K+515% | ||
| $6.66M+276% | $6.39M+231% | $3.87M+188% | $1.62M-41.2% | $1.77M-12.3% | ||
| -$41.63M-198% | $42.94M— | $86.21M+1,009% | $2.78M+106% | -$13.96M-113% | ||
| $3.87M+131% | $3.63M+104% | $7.8M+224% | $939K+107% | -$12.37M-111% | ||
| -$24.26M+51.7% | $56.78M— | $141.14M+2,326% | $11.22M+117% | -$50.18M-144% | ||
| -$10.91M-41.2% | $12M— | $23.86M+2,765% | $6.38M+147% | -$7.73M-128% | ||
| -$13.35M+68.6% | $44.78M+244% | $117.27M+1,735% | $4.85M+109% | -$42.45M-149% | ||
| -25.8%+67.8pp | 75.1%+148pp | 101.6%+115pp | 10.2%+135pp | -93.6%-372pp | ||
| -$0.67+69.7% | $2.18+230% | $5.68+1,556% | $0.24+108% | -$2.21-147% | ||
| -$0.67+69.7% | $2.33+235% | $5.99+1,636% | $0.25+109% | -$2.21-145% | ||
| 19.9M+3.6% | 20.3M+11.0% | 20.6M+12.0% | 19.9M+10.5% | 19.2M+5.9% | ||
| 19.9M+3.6% | 19.3M+5.7% | 19.6M+6.3% | 19.3M+7.2% | 19.2M+8.2% | ||
| $8.1M-1.9% | $8.1M-2.0% | $8.1M-1.9% | $8.26M0.0% | $8.26M+0.9% | ||
| $3.27M-32.5% | $2.99M+5.5% | $3.8M+55.2% | $2.91M0.0% | $4.85M+68.3% | ||
| $0-100% | $0+100% | $833K+111% | -$1.28M— | $443K— | ||
| -$49.23M— | $14.78M— | $75.89M+2,605% | $0— | $0— | ||
| -$1.18M+53.0% | —— | -$443K+95.3% | $1.37M+104% | -$2.5M-14.1% | ||
| $51.72M+14.1% | $59.67M+39.4% | $115.46M+123% | $47.63M+14.7% | $45.33M+46.3% | ||
| $17.37M+148% | $13.84M+244% | $54.93M+1,648% | $8.44M+144% | -$36.22M-1,312% | ||
| $25.58M+193% | $22.06M+2,284% | $63.2M+421% | $16.97M+266% | -$27.45M-334% | ||
| $25.58M+193% | $22.06M+2,284% | $63.2M+421% | $16.97M+266% | -$27.45M-334% | ||
| 49.5%+110pp | 37%+39.3pp | 54.7%+31.3pp | 35.6%+60.3pp | -60.5%-98.5pp | ||
| $17.37M+148% | $13.84M+244% | $54.93M+1,648% | $8.44M+144% | -$36.22M-1,312% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ligand Pharmaceuticals's profit margins?
- Gross margin is 91.9% and operating margin is 34.5%, with a 55.9% net margin.
- Where does Ligand Pharmaceuticals's income statement data come from?
- Every line is extracted from Ligand Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.